At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 21, 2026 at 16:15 ET
Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA to appeal a Complete Response Letter (CRL) for its ONS-5010/ LYTENAVA™ biologics license application. A formal decision from the FDA is expected in May 2026.
- Company held an FDR meeting with the FDA on April 21, 2026, to appeal a CRL issued on December 30, 2025, for ONS-5010/ LYTENAVA™.
- The drug is under development for wet AMD and has already received marketing authorization in the EU and UK.
- The company expects a formal decision from the FDA in May 2026.
- No financial figures or material changes to operations were disclosed.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access